Clinical Trial Update: An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

An open Phase 2/Phase 3 trial evaluating the tolerability of AVANZ Mite Mix Immunotherapy for allergic rhinitis due to dust mite has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AVANZ Mite Mix Immunotherapy (mite mix immunotherapy)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinitis Due to Dust Mite | Phase 2, Phase 3 | Status: COMPLETED